banner
home azienda prodotti anatomia contatti
integratori
ombra_sx
red_line
down
icon
 More info  
Diabetic retinopathy is the main cause of blindness between the ages of 20 and 70. Every year, 50,000 diabetic patients develop diabetic retinopathy in Italy alone.
This progressive and invalidating disease is certainly one of the most unfortunate complications of diabetes. In order to minimize the damage caused by this disease, it is important to take suitable preventive measures; diabetic patients must constantly check their glycemic index following the instructions of specialized centres. It is also very important to establish a support therapy which aims to help protect the retinal vascular system, the deterioration of which causes a series of complications which lead to increased deterioration of the patient’s vision which can end in blindness.
 
down
down
icon
 Download  

Info in Vista 2006 N.1 RETINOPARIA DIABETICA

icon_pdf
 Download the file (2,0 Mb)
 
down
down
icon_biblio
 Bibliography

1) Funatsu H, Yamashita H.
Pathophysiology of Diabetic Retinopathy.
Drug News Perspect. 2002 Dec;15(10):633-639.

2. Kohner EM, Patel V, Rassam SM.
Role of blood flow and impaired autoregulation in the pathogenesis of diabetic retinopathy.
Diabetes. 1995 Jun;44(6):603-7. Review.

3. Wong TY, Klein R, Duncan BB, Nieto FJ, Klein BE, Couper DJ, Hubbard LD,
Sharrett AR. Racial Differences in the Prevalence of Hypertensive Retinopathy.
Hypertension. 2003 Mar 24

4. Chatterjee S, Chattopadhyay S, Hope-Ross M, Lip PL, Chattopadhya S.
Hypertension and the eye: changing perspectives.
J Hum Hypertens. 2002 Oct;16(10):667-75. Review.

5. Hyman BN.
The Eye as a Target Organ: An Updated Classification of Hypertensive
Retinopathy. J Clin Hypertens (Greenwich). 2000 May;2(3):194-197.

6. Sayag D, Gotzamanis A, Brugniart C, Segal A, Ducasse A, Chambre V,
Glacet-Bernard A. [Retinal vein occlusion and carotid Doppler imaging]
J Fr Ophtalmol. 2002 Oct;25(8):826-30. French.

7. Ueda Y, Kanazawa S, Ohira A, Miyamura N, Takaki T, Kitaoka T, Amemiya T.
Retinal vascular obstruction and asymptomatic cerebral infarction.
Jpn J Ophthalmol. 2002 Mar-Apr;46(2):209-14.

8. Recchia FM, Brown GC.
Systemic disorders associated with retinal vascular occlusion.
Curr Opin Ophthalmol. 2000 Dec;11(6):462-7. Review.

9. Bhagat N, Goldberg MF, Gascon P, Bell W, Haberman J, Zarbin MA.
Central retinal vein occlusion: review of management.
Eur J Ophthalmol. 1999 Jul-Sep;9(3):165-80. Review.

10. Wong VK.
Retinal venous occlusive disease.
Hawaii Med J. 1997 Oct;56(10):289-91. Review.

11. Laatikainen LT.
Management of retinal vein occlusion.
Curr Opin Ophthalmol. 1992 Jun;3(3):372-8. Review.

12. Glacet-Bernard A, Coscas G, Chabanel A, Zourdani A, Lelong F, Samama MM. A randomized, double-masked study on the treatment of retinal vein occlusion with troxerutin.
Am J Ophthalmol. 1994 Oct 15;118(4):421-9.

13. Agolini G, Cavallini GM.
[Long-term therapy of retinal vasculopathies with oral administration of high
doses of O-(beta-hydroxyethyl)-rutoside] Clin Ter. 1987 Jan 31;120(2):101-10.

14. Lumbroso Bruno
"Retinopatia Diabetica", pp 9-11, Casa Ed. ESAM Futura Roma, 1991. (modificata)

15. Incandela L, Cesarone MR, Cacchio M, De Sanctis MT, Santavenere C, D'Auro MG, Bucci M, Belcaro G.
Total triterpenic fraction of Centella asiatica in chronic venous insufficiency
and in high-perfusion microangiopathy.
Angiology. 2001 Oct; 52 Suppl 2:S9-13.

16. Cesarone MR, Incandela L, De Sanctis MT, Belcaro G, Bavera P, Bucci M, Ippolito E.
Evaluation of treatment of diabetic microangiopathy with total triterpenic
fraction of Centella asiatica: a clinical prospective randomized trial with a
microcirculatory model.
Angiology. 2001 Oct;52 Suppl 2:S49-54.

17. Cesarone MR, Incandela L, De Sanctis MT, Belcaro G, Geroulakos G, Griffin M, Lennox A, Di Renzo AD, Cacchio M, Bucci M.
Flight microangiopathy in medium- to long-distance flights: prevention of edema and microcirculation alterations with total triterpenic fraction of Centella asiatica. Angiology. 2001 Oct;52 Suppl 2:S33-7.

18. Cesarone MR, Laurora G, De Sanctis MT, Incandela L, Grimaldi R, Marelli C,
Belcaro G. [The microcirculatory activity of Centella asiatica in venous insufficiency. A double-blind study] Minerva Cardioangiol. 1994 Jun;42(6):299-304. Italian.

19. Cesarone MR, Laurora G, De Sanctis MT, Belcaro G.
[Activity of Centella asiatica in venous insufficiency] Minerva Cardioangiol. 1992 Apr;40(4):137-43. Italian.

20. Belcaro GV, Grimaldi R, Guidi G.
Improvement of capillary permeability in patients with venous hypertension
after treatment with TTFCA. Angiology. 1990 Jul;41(7):533-40.

21. Droy-Lefaix MT, Cluzel J, Menerath JM, Bonhomme B, Doly M.
Antioxidant effect of a Ginkgo biloba extract (EGb 761) on the retina.
Int J Tissue React. 1995;17(3):93-100.

22. Ellnain-Wojtaszek M, Kruczynski Z, Kasprzak J.
Investigation of the free radical scavenging activity of Ginkgo biloba L. leaves.
Fitoterapia. 2003 Feb;74(1-2):1-6.

23. Koltringer P, Langsteger W, Klima G, Reisecker F, Eber O.
[Hemorheologic effects of ginkgo biloba extract EGb 761. Dose-dependent effect of EGb 761 on microcirculation and viscoelasticity of blood]
Fortschr Med. 1993 Apr 10;111(10):170-2. German.

24. Shen L, Cui Y.
[Effects of the leaf of Ginkgo biloba L. extract on blood rheology in animals]
Zhongguo Zhong Yao Za Zhi. 1998 Oct;23(10):622-3, 640- inside back cover.

25. Pepe C, Rozza A, Veronesi G.
[The evaluation by video capillaroscopy of the efficacy of a Ginkgo biloba
extract with L-arginine and magnesium in the treatment of trophic lesions in
patients with stage-IV chronic obliterating arteriopathy] Minerva Cardioangiol. 1999 Jun; 47(6):223-30. Italian.

26. Lotz-Winter H.
On the pharmacology of bromelain: an update with special regard to animal
studies on dose-dependent effects. Planta Med. 1990 Jun;56(3):249-53. Review.

27. Taussig SJ, Yokoyama MM, Chinen A, Onari K, Yamakido M.
Bromelain: a proteolytic enzyme and its clinical application. A review.
Hiroshima J Med Sci. 1975 Sep;24(2-3):185-93. Review.

28. Erdinçler, D. S., Karakoç, Y et al
The effect of Ginkgo biloba glycoside on the blood viscosity and erythrocyte deformability.
Clinical Hemorheology 1996, Vol. 16, No. 3, pp. 271-276.

29. Venditti P, Masullo P, Di Meo S, Agnisola C.
Protection against ischemia-reperfusion induced oxidative stress by vitamin E
treatment. Arch Physiol Biochem. 1999 Feb;107(1):27-34.

30. Rose RC, Bode AM.
Biology of free radical scavengers: an evaluation of ascorbate.
FASEB J. 1993 Sep;7(12):1135-42. Review.

31. Retsky KL, Freeman MW, Frei B.
Ascorbic acid oxidation product(s) protect human low density lipoprotein
against atherogenic modification. Anti- rather than prooxidant activity of
vitamin C in the presence of transition metal ions.
J Biol Chem. 1993 Jan 15;268(2):1304-9.

32. Yasuo Oyama, Paul A. Fuchs et al.
Myricetin and quercetin, the flavonoid constituents of Ginkgo biloba extract, greatly reduce oxidative metabolism in both resting and Ca++-loaded brain neurons.
Brain Research 635 (1994) 125-129.

33. Schonlau F, Rohdewald P.
Pycnogenol for diabetic retinopathy. A review.
Int Ophthalmol. 2001;24 (3): 161-71.

34. Spadea L, Balestrazzi E.
Treatment of vascular retinopathies with Pycnogenol.
Phytother Res. 2001 May;15 (3): 219-23.

35. Packer L, Rimbach G, Virgili F.
Antioxidant activity and biologic properties of a procyanidin-rich extract from pine (Pinus maritima) bark, pycnogenol.
Free Radic Biol Med. 1999 Sep;27 (5-6): 704-24.

36. Rohdewald P.
Review: The French maritime pine bark extract (Pycnogenol).
Int J Clin Pharm Ther. 2002 (40): 158-168.

37. Cho KJ, Jun CH et al.
Inhibition mechanisms of bioflavonoids extracted from the bark of pinus maritima on the expression of proinflammatory cytokines.
Ann NY Acad Sci. 2001 (928): 141-156.
 
down
 
maxiven
Composition
GINKGO BILOBA extract 130 mg
MARITIME PINE bark extract 50 mg
RUTIN 30 mg
CENTELLA ASIATICA extract 50 mg
PINEAPPLE powder 30 mg
VITAMIN E 10 mg
VITAMIN C 60 mg
 
Description

Dietary supplement of vitamins and bioflavonoids with vegetable extracts

MAXIVEN® capsules are recommended for retinal vascular disorders (diabetic, hypertensive and vascular retinopathy)

MAXIVEN® capsules help in the targeted protection of the retinal vascular system thanks to the completeness of its formulation. The effect of MAXIVEN capsules is achieved via the combination of various actions performed by its components: the vasoprotective action of centella, rutin and oligomeric proanthocyanidin (OPC), the vasoprotective and hemoreologic effect of ginkgo biloba and oligomeric proanthocyanidin, the antiedemagenic effect of bromelin, and the antioxidant effect of vitamin C, vitamin E and polyphenols.
MAXIVEN® capsules help to prevent and/or slow down the progression of retinal damage caused by diabetes.
 

Diabetic retinopathy is the main cause of blindness between the ages of 20 and 70.

grafico

Every year, 50,000 diabetic patients develop diabetic retinopathy in Italy.

GINKGO BILOBA – Vasoregulatory and hemoreologic effect
Helps to keep the fluidity of the blood within normal limits and encourages blood flow in the small blood vessels. Increases the speed of blood flow to the eye.

GINKGO BILOBA, VITAMIN E, VITAMIN C – Antioxidant effect
Neutralize free radicals, protect the integrity of vessel and tissue structures from oxidation damage..

MARITIME PINE bark extract – Vasoprotective and antioxidant effect
The oligomeric proanthocyanidins contained in maritime pine bark are very effective in the protection of the walls of small blood vessels increasing their tone and resistance. They contribute to the normalization of capillary permeability and protect the integrity of collagen. Oligomeric proanthocyanidins also protect the blood vessel walls from oxidative damage by free radicals

RUTIN and CENTELLA – Vasoprotective effect
Rutin improves the functioning of endothelial cells and increases the release of fibrynolitic substances. Centella modulates the production of collagen which strengthens blood vessel walls and encourages perivasal fibrinolysis with improvement of metabolic exchanges and therefore tissue trophism. Rutin and Centella, thanks to their synergy of action, contribute both to the protection of the endothelium and the connectival structure of small blood vessels resulting in an increase in the resistance, elasticity and tone of the capillary wall.

BROMELIN - Proteolytic and antiedemagenic effect
This is contained in the pineapple extract and is able to reduce large proteins, which as a result of the stasis of interstitial liquid, adhere to the capillary endothelium and falsify its permeability, to small fragments. In this way, reabsorption of oedemas is facilitated.
 
Product Use

DOSAGE AND ADMINISTRATION
One tablet a day to be swallowed with water, ideally on an empty stomach.

PACKAGE
Box containing a blister pack of 20 capsules.
 
 
flaguk © BIOOS Italia 2007 - Term of use and privacy policy - All rights reserved - Credits - end